{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:14Z","timestamp":1793316254667,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10147-026-03067-2","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:05:23Z","timestamp":1779815123000},"page":"1597-1606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Changes in plasma cfDNA ERBB2 copy number reflect prognosis in HER2-positive gastric cancer: a correlative analysis of the KSCC-TROX A2 study"],"prefix":"10.1007","volume":"31","author":[{"given":"Yuki","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kashiwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Nambara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakanoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Yoshizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-9366","authenticated-orcid":false,"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"9","key":"3067_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/jjco\/hyv088","volume":"45","author":"M Hori","year":"2015","unstructured":"Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H (2015) Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45(9):884\u2013891","journal-title":"Jpn J Clin Oncol"},{"issue":"9742","key":"3067_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697","journal-title":"Lancet"},{"key":"3067_CR3","volume-title":"Japanese Gastric Cancer Treatment Guidelines 2018","author":"Japanese Gastric Cancer Association","year":"2018","unstructured":"Japanese Gastric Cancer Association (2018) Japanese Gastric Cancer Treatment Guidelines 2018, 5th edn. Kanehara & Co., Ltd., Tokyo","edition":"5"},{"key":"3067_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.09.024","volume":"105","author":"H Saeki","year":"2018","unstructured":"Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M et al (2018) Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer 105:41\u201349","journal-title":"Eur J Cancer"},{"issue":"17","key":"3067_CR5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.19.03077","volume":"38","author":"A Makiyama","year":"2020","unstructured":"Makiyama A, Sukawa Y, Kashiwada T, Takahashi M, Tanizawa Y et al (2020) Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J Clin Oncol 38(17):1919\u20131927","journal-title":"J Clin Oncol"},{"issue":"3","key":"3067_CR6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","volume":"22","author":"S Seo","year":"2019","unstructured":"Seo S, Ryu MH, Park YS, Ahn JY, Park Y, Park SR et al (2019) Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer 22(3):527\u2013535","journal-title":"Gastric Cancer"},{"issue":"4","key":"3067_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara K, Van Cutsem E, G\u00fcm\u00fc\u015f M, Lonardi S, De La Fouchardi\u00e8re C, Coutzac C et al (2025) Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N Engl J Med 393(4):336\u2013348","journal-title":"N Engl J Med"},{"issue":"1","key":"3067_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10120-016-0599-z","volume":"20","author":"K Shoda","year":"2017","unstructured":"Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J et al (2017) Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer 20(1):126\u2013135","journal-title":"Gastric Cancer"},{"issue":"11","key":"3067_CR9","doi-asserted-by":"publisher","first-page":"e21339","DOI":"10.1016\/j.heliyon.2023.e21339","volume":"9","author":"S Klein-Scory","year":"2023","unstructured":"Klein-Scory S, Ladigan-Badura S, Mika T, Verdoodt B, Tannapfel A, Pohl M et al (2023) Liquid biopsy based HER2 amplification status in gastric cancer patients indicates clinical response. Heliyon 9(11):e21339","journal-title":"Heliyon"},{"key":"3067_CR10","doi-asserted-by":"publisher","first-page":"e000600","DOI":"10.1136\/esmoopen-2019-000600","volume":"5","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Shitara K (2020) Development of circulating tumour DNA analysis for gastrointestinal cancers. ESMO Open 5:e000600","journal-title":"ESMO Open"},{"issue":"224","key":"3067_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies.\u00a0Sci Transl Med 6(224):224ra24","journal-title":"Sci Transl Med"},{"issue":"4","key":"3067_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C et al (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17(4):223\u2013238","journal-title":"Nat Rev Cancer"},{"key":"3067_CR13","doi-asserted-by":"publisher","first-page":"102861","DOI":"10.1016\/j.ebiom.2020.102861","volume":"57","author":"T Fukuhara","year":"2020","unstructured":"Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S et al (2020) Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study. EBioMedicine 57:102861","journal-title":"EBioMedicine"},{"issue":"313","key":"3067_CR14","doi-asserted-by":"publisher","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","volume":"7","author":"G Schiavon","year":"2015","unstructured":"Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N et al (2015) Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 7(313):313ra182. https:\/\/doi.org\/10.1126\/scitranslmed.aac7551","journal-title":"Sci Transl Med"},{"issue":"1","key":"3067_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41467-018-03215-x","volume":"9","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X et al (2018) Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun 9(1):896","journal-title":"Nat Commun"},{"issue":"11","key":"3067_CR16","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M et al (2024) ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med 30(11):3272\u20133283","journal-title":"Nat Med"},{"issue":"1","key":"3067_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13046-024-03105-9","volume":"43","author":"E Giordani","year":"2024","unstructured":"Giordani E, Allegretti M, Sinibaldi A, Michelotti F, Ferretti G, Ricciardi E et al (2024) Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients. J Exp Clin Cancer Res 43(1):182","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"3067_CR18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s10120-022-01313-w","volume":"25","author":"MJM Van Velzen","year":"2022","unstructured":"Van Velzen MJM, Creemers A, Van Den Ende T, Schokker S, Krausz S, Reinten RJ et al (2022) Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer. Gastric Cancer 25(5):906\u2013915","journal-title":"Gastric Cancer"},{"issue":"8","key":"3067_CR19","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41416-020-1002-8","volume":"123","author":"MR Openshaw","year":"2020","unstructured":"Openshaw MR, Suwaidan AA, Ottolini B, Fernandez-Garcia D, Richards CJ, Page K et al (2020) Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. Br J Cancer 123(8):1271\u20131279","journal-title":"Br J Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03067-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:40Z","timestamp":1784997340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03067-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3067"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03067-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EO reports research funding from Guardant Health, Inc., and reports honoraria from Chugai Pharmaceutical, Eli Lilly, Takeda Pharmaceutical, Bristol Myers Squibb, and Ono Pharmaceutical. KS reports honoraria from Takeda Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Qiagen, Inc., and Life Technologies Japan Ltd. outside the submitted work. KN reports research funding from West Japan Oncology Group, Otsuka, Hitachi, Osaka Minami Hospital, Thoracic Oncology Research Group, Eli Lilly Japan, Okayama University, Japan Breast Cancer Research Group, Nippon Boehringer Ingelheim, and Kyushu Study Group of Clinical Cancer, and reports honoraria from AstraZeneca, MSD, Nichirei Biosciences, Guardant Health, SymBio, Chugai, Eli Lilly Japan, Maruho, Janssen, Otsuka, Daiichi Sankyo, Nittobo Medical, and Nihon Servier outside the submitted work. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}